Trium Capital’s Inozyme Pharma INZY Stock Holding History

Trium Capital’s Portfolio INZY Stock Details INZY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-3,173,454	Closed	-$12.7M	–	66
2025 Q2	$12.7M	Buy	+3,173,454	New	+$7.86M	3.16%	11

Trium Capital's INZY Position: Q3 2025 in Review

Trium Capital sold out of Inozyme Pharma (INZY) in Q3 2025, closing a stake of 3,173,454 shares — an estimated $12.7M sold.

Trium Capital first reported a position in INZY in Q2 2025 and held it in 1 quarter. The position peaked at $12.7M in Q2 2025. 0 funds tracked by Wall St. Rank hold INZY as of Q3 2025.

Trium Capital reported no remaining Inozyme Pharma position as of Q3 2025 after selling out during the quarter.
Trium Capital sold 3,173,454 Inozyme Pharma shares in Q3 2025, an estimated $12.7M.
Trium Capital first reported a position in Inozyme Pharma in Q2 2025 and held it in 1 quarter.
Trium Capital's Inozyme Pharma position peaked at $12.7M in Q2 2025.
0 funds tracked by Wall St. Rank held Inozyme Pharma as of Q3 2025.

Based on Trium Capital's 13F filing for Q3 2025, filed 16 Oct 2025.